PDS Biotechnology Corp (PDSB)

[BigEars]

Very interesting but why would they get AA or breakthrough designation when Bintrafusp alfa in HPV positive patients did not receive one of those (yet)?

Bintrafusp alfa is now in phase 2 trial (open label single arm 146 patients) and results will probably be published in 1Q2022.

As for previous results - The median overall survival among the 43 patients was 16.2 months. This “compares very favorably” to the survival of 9 to 11 months seen in patients with HPV-related cancers in previous trials testing immune checkpoint inhibitors that target PD-1 or PD-L1, noted Julius Strauss, M.D., of NCI’s Center for Cancer Research (CCR), who presented the results of the trial in Atlanta.

https://www.cancer.gov/news-events/cancer-currents-blog/2019/immunotherapy-y-trap-hpv-cancershttps://www.cancer.gov/news-events/cancer-currents-blog/2019/immunotherapy-y-trap-hpv-cancers